| Literature DB >> 29113332 |
Romain Gioia1, Simon Drouin1, Manon Ouimet1, Maxime Caron1, Pascal St-Onge1, Chantal Richer1, Daniel Sinnett1,2.
Abstract
Childhood acute lymphoblastic leukemia (cALL) accounts for 25% of pediatric cancers and is one of the leading causes of disease-related death in children. Although long non-coding RNAs (lncRNAs) have been implicated in cALL etiology, progression, and treatment response, little is known about their exact functional role. We had previously sequenced the whole transcriptome of 56 cALL patients and identified lncRNA transcripts specifically silenced in tumoral cells. Here we investigated the impact of restoring the expression of three of these (RP11-624C23.1, RP11-203E8, and RP11-446E9) in leukemic cell lines had dramatic impact on cancer hallmark cellular phenotypes such as apoptosis, cell proliferation and migration, and DNA damage response. Interestingly, both RP11-624C23.1 and RP11-203E8 had very similar impacts on DNA damage response, specifically displaying lower γ-H2A.X and higher apoptosis levels than control cells in response to genotoxic stress. These results indicate that silencing RP11-624C23.1 or RP11-203E8 could provide a selective advantage to leukemic cells by increasing resistance to genotoxic stress, possibly by modulating the DDR pathway. Since genotoxic agents are fundamental parts of antineoplastic treatment, further investigation of the mechanisms these lncRNAs impact would provide novel and interesting avenues for overcoming treatment resistance.Entities:
Keywords: DNA damage response; acute lymphoblastic leukemia; apoptosis; long non-coding RNA; treatment resistance
Year: 2017 PMID: 29113332 PMCID: PMC5655227 DOI: 10.18632/oncotarget.20817
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1The lncRNAs RP11-624C23.1 and RP11-203E8 are involved in camptothecin resistance and DNA damage response
Reh-pLenti, Reh-RP11-624C23.1, Reh-RP11-203E8, Reh-RP11-446E9, Reh-RP11-624C23.1-sh2, Reh-RP11-203E8-sh2, and Reh-RP11-446E9-sh2 were treated with camptothecin (CPT) 10 μM for six hours. Apoptosis (A) and γ-H2A.X (B) were then measured. *, *** and ****P ≤ 0.05, ≤ 0.001 and ≤ 0.0001, respectively. The GM12878 non-leukemic lymphoid cell line was used as a normal cell control.
Figure 2The lncRNA RP11-446E9 regulates cell proliferation and migration
Four-day proliferation tests (A) and migration assays (B) were performed on Reh-pLenti (Control), Reh-RP11-624C23.1 (RP11-624C23), Reh-RP11-203E8 (RP11-203E8), Reh-RP11-446E9 (RP11-446E9), and Reh-RP11-446E9-sh1 (Rescue) cell lines. *, **, *** and ****P ≤ 0.05, ≤ 0.01, ≤ 0.0005 and ≤ 0.0001 respectively.